At a glance
ClinicalIndex Comparison RecordStandardized by ClinicalIndex from the ClinicalTrials.gov record · verify against the source.
A Phase 2 Study of Anti-PD-L1 Antibody (Atezolizumab) in Chondrosarcoma and Clear Cell Sarcoma
In Brief
A Phase 2 clinical trial evaluating Atezolizumab, Biopsy Procedure, and 2 other interventions for Central Chondrosarcoma, Grade 2 and 5 related conditions. Active but no longer recruiting, targeting 27 participants across 15 sites in 2 countries.
Signals
Detailed Summary
This phase II trial studies how well atezolizumab works in treating patients with chondrosarcoma or clear cell sarcoma that is newly diagnosed, cannot be removed by surgery (unresectable), or has spread to other places in the body (metastatic). Immunotherapy with monoclonal antibodies, such as atezolizumab, may help the body's immune system attack the cancer, and may interfere with the ability of tumor cells to grow and spread.
Study Details
Timeline
Arms & Interventions
Patients receive atezolizumab IV over 30-60 minutes on ay 1. Cycles repeat every 21 days in the absence of disease progression or unacceptable toxicity. Patients undergo CT scans and undergo biopsy and collection of blood samples on study.
Interventions
Given IV
Correlative studies
Correlative studies
Undergo CT scan